deltatrials
Completed PHASE3 INTERVENTIONAL 2-arm NCT01670240

Adalimumab in the Treatment of Chronic Pouchitis (ADAP)

Adalimumab (Humira) in the Treatment of Chronic Pouchitis

Sponsor: Aarhus University Hospital

Updated 6 times since 2017 Last updated: Jan 27, 2016 Started: Aug 31, 2012 Primary completion: Sep 30, 2015 Completion: Jan 31, 2016
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT01670240, this PHASE3 trial focuses on Pouchitis and Ulcerative Colitis and remains completed. Sponsored by Aarhus University Hospital, it has been updated 6 times since 2012, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshotCompleted~Feb 2017 – ~Jun 2018 · 16 months · monthly snapshotCompleted~Jun 2018 – ~Jan 2021 · 31 months · monthly snapshotCompleted~Jan 2021 – ~Jul 2024 · 42 months · monthly snapshotCompleted~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotCompleted~Sep 2024 – present · 24 months · monthly snapshotCompleted

Change History

6 versions recorded
  1. Sep 2024 — Present [monthly]

    Completed PHASE3

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE3

  3. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE3

  4. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE3

  5. Feb 2017 — Jun 2018 [monthly]

    Completed PHASE3

Show 1 earlier version
  1. Jan 2017 — Feb 2017 [monthly]

    Completed PHASE3

    First recorded

Aug 2012

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Aarhus University Hospital
  • AbbVie
  • Hvidovre University Hospital
  • Odense University Hospital
  • University of Southern Denmark
Data source: Odense University Hospital

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations